Baseline characteristics
| . | NPM1c . | NPM1wt . | P . |
|---|---|---|---|
| Patients, n (%) | 206 (12) | 1516 (88) | |
| Median age, y (range) | 64 (17-91) | 64 (16-90) | .6 |
| Male, n (%) | 85 (42) | 938 (62) | <.0001 |
| Hemoglobin, median g/dL (range) | 9.3 (6-15) | 9.1 (4-18) | .1 |
| WBC, median x 109/L (range) | 8.1 (0.1-227) | 3.6 (0.1-339) | <.0001 |
| Platelet count, median x 109/L (range) | 45 (4-624) | 43 (1-1552) | .007 |
| Peripheral blast %, median (range) | 37 (0-100) | 8 (0-100) | <.0001 |
| BM blast %, median (range) | 60 (0-99) | 30 (0-98) | <.0001 |
| t-AML, n (%) | 16 (8) | 221 (15) | .007 |
| s-AML, n (%) | 6 (3) | 236 (16) | <.0001 |
| Cytogenetics (194/1451) | <.0001 | ||
| Diploid, n (%) | 118/194 (61) | 445/1451 (31) | |
| Complex, −5, −7, n (%) | 15/194 (8) | 554/1451 (38) | |
| Other, n (%) | 61/194 (31) | 452/1451 (31) | |
| Mutations | |||
| DNMT3A (%) | 98/195 (50) | 245/1412 (17) | <.0001 |
| FLT3-ITD (%) | 99/201 (49) | 162/1451 (11) | <.0001 |
| TET2 (%) | 50/159 (31) | 760/1174 (65) | <.0001 |
| IDH1 (%) | 40/196 (20) | 102/1457 (7) | <.0001 |
| IDH2 (%) | 40/198 (20) | 160/1455 (11) | .0003 |
| KRAS/NRAS (%) | 36/195 (19) | 279/1461 (19) | 1.0 |
| WT1 (%) | 30/156 (19) | 111/1065 (10) | .009 |
| FLT3-D835 (%) | 25/198 (13) | 64/1454 (4) | <.0001 |
| ASXL1 (%) | 10/154 (6) | 242/1116 (22) | <.0001 |
| TP53 (%) | 12/189 (6) | 354/1432 (25) | <.0001 |
| RUNX1 (%) | 7/155 (5) | 244/1102 (22) | <.0001 |
| Lines of therapy | |||
| S1 (%) | 132 (64) | 953 (63) | .8 |
| S2 (%) | 32 (15) | 277 (18) | .3 |
| ≥S3 (%) | 42 (21) | 287 (19) | .5 |
| Duration of first remission | |||
| ≤ 6 mo | 18/44 (41%) | 98/242 (40%) | 1.0 |
| Between 6 and 12 mo | 12/44 (27%) | 61/242 (25%) | .9 |
| ≥12 mo | 14/44 (32%) | 83/242 (34%) | .9 |
| . | NPM1c . | NPM1wt . | P . |
|---|---|---|---|
| Patients, n (%) | 206 (12) | 1516 (88) | |
| Median age, y (range) | 64 (17-91) | 64 (16-90) | .6 |
| Male, n (%) | 85 (42) | 938 (62) | <.0001 |
| Hemoglobin, median g/dL (range) | 9.3 (6-15) | 9.1 (4-18) | .1 |
| WBC, median x 109/L (range) | 8.1 (0.1-227) | 3.6 (0.1-339) | <.0001 |
| Platelet count, median x 109/L (range) | 45 (4-624) | 43 (1-1552) | .007 |
| Peripheral blast %, median (range) | 37 (0-100) | 8 (0-100) | <.0001 |
| BM blast %, median (range) | 60 (0-99) | 30 (0-98) | <.0001 |
| t-AML, n (%) | 16 (8) | 221 (15) | .007 |
| s-AML, n (%) | 6 (3) | 236 (16) | <.0001 |
| Cytogenetics (194/1451) | <.0001 | ||
| Diploid, n (%) | 118/194 (61) | 445/1451 (31) | |
| Complex, −5, −7, n (%) | 15/194 (8) | 554/1451 (38) | |
| Other, n (%) | 61/194 (31) | 452/1451 (31) | |
| Mutations | |||
| DNMT3A (%) | 98/195 (50) | 245/1412 (17) | <.0001 |
| FLT3-ITD (%) | 99/201 (49) | 162/1451 (11) | <.0001 |
| TET2 (%) | 50/159 (31) | 760/1174 (65) | <.0001 |
| IDH1 (%) | 40/196 (20) | 102/1457 (7) | <.0001 |
| IDH2 (%) | 40/198 (20) | 160/1455 (11) | .0003 |
| KRAS/NRAS (%) | 36/195 (19) | 279/1461 (19) | 1.0 |
| WT1 (%) | 30/156 (19) | 111/1065 (10) | .009 |
| FLT3-D835 (%) | 25/198 (13) | 64/1454 (4) | <.0001 |
| ASXL1 (%) | 10/154 (6) | 242/1116 (22) | <.0001 |
| TP53 (%) | 12/189 (6) | 354/1432 (25) | <.0001 |
| RUNX1 (%) | 7/155 (5) | 244/1102 (22) | <.0001 |
| Lines of therapy | |||
| S1 (%) | 132 (64) | 953 (63) | .8 |
| S2 (%) | 32 (15) | 277 (18) | .3 |
| ≥S3 (%) | 42 (21) | 287 (19) | .5 |
| Duration of first remission | |||
| ≤ 6 mo | 18/44 (41%) | 98/242 (40%) | 1.0 |
| Between 6 and 12 mo | 12/44 (27%) | 61/242 (25%) | .9 |
| ≥12 mo | 14/44 (32%) | 83/242 (34%) | .9 |
Cytogenetics, mutations and duration of first remission values are mutated/evaluable (%).
BM, bone marrow; s-AML, AML secondary to antecedent hematologic neoplasm; S1, salvage 1; S2, salvage 2; S3, salvage 3; t-AML, therapy-related AML; WBC, white blood cell.